Table 3.

Management and outcome at last follow-up

CharacteristicKidney (+) MCVEssential MCVPrimary Sjögren SyndromeHematologic malignancyP Value
Follow-up (months), mean±SD49.9±45.549.3±40.664.8±63.639.2±33.80.57
Relapses, n (%)32 (42.7)16 (45.7)10 (58.8)6 (26.1)0.10
 Delay to 1st relapse (months), mean±SD28.2±19.419.6±10.739±24.732.3±18.90.19
 Renal relapse, n (%)24 (75)13 (81.3)8 (80)3 (50)0.29
Administered treatments
 Steroids alone, n (%)12 (15.8)11 (30.6)1 (5.9)0 (0)0.003
 RTX + Steroids, n (%)20 (26.3)10 (27.8)3 (17.7)7 (30.4)0.64
 CYC + Steroids, n (%)20 (26.3)7 (19.4)7 (41.2)6 (26.1)0.25
 CYC + RTX + Steroids, n (%)21 (27.6)6 (16.7)6 (35.3)9 (39.1)0.12
 Other treatment, n (%)3 (3.95)2 (5.6)0 (0)1 (4.4)0.62
 Plasma exchanges, n (%)25 (32.9)8 (22.2)10 (58.8)7 (30.4)0.03
Renal parameters
 Proteinuria >0.5 g/d, n (%)12 (19)5 (17.2)3 (21.4)4 (20)0.94
 Hematuria, n (%)18 (28.6)7 (24.1)6 (42.9)5 (25)0.41
 GFRLFup, mean±SD50.2±26.148.3±29.348.1±2355±23.10.57
 <60 ml/min per 1.73 m2, n (%)45 (57.7)22 (57.9)11 (64.7)12 (52.2)0.73
  <30 ml/min per 1.73 m2, n (%)20 (25.6)13 (34.2)3 (17.6)4 (17.4)0.24
 <15 ml/min per 1.73 m2, n (%)7 (9)5 (13.2)2 (11.8)0 (0)0.20
Renal outcome0.12
 NR, n (%)21 (26.9)11 (28.9)5 (29.4)5 (21.7)
 PR, n (%)18 (23.1)10 (26.3)3 (17.6)5 (21.7)
 CR, n (%)39 (50)17 (44.7)9 (52.9)13 (56.5)
Clinical outcome0.21
 NR, n (%)16 (17.9)6 (15.8)4 (23.5)4 (17.4)
 PR, n (%)18 (23.1)12 (31.6)3 (17.6)3 (13)
 CR, n (%)46 (59)20 (52.6)10 (58.8)16 (69.6)
New-onset hematologic malignancy, n (%)5 (8.9)2 (5.6)3 (16.7)0.37
Severe Infections, n (%)23 (29.1)12 (31.6)4 (22.2)7 (30.4)0.76
Death, n (%)19 (24)9 (23.7)5 (27.8)5 (21.7)0.90
  • RTX, rituximab; CYC, cyclophosphamide; GFRLFup, glomerular filtration rate at last follow-up expressed in ml/min per1.73 m2; NR, nonresponder; PR, partial remission; CR, complete remission.